Bong-sook Baek

Array ( [id] => 17595223 [patent_doc_number] => 20220144796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => 2-[Thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use therof as medicament [patent_app_type] => utility [patent_app_number] => 17/518608 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17518608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398038 [patent_doc_number] => 20220040128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUM [patent_app_type] => utility [patent_app_number] => 17/502562 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26976 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17502562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17759906 [patent_doc_number] => 20220233518 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/498507 [patent_app_country] => US [patent_app_date] => 2021-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63816 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593362 [patent_doc_number] => 20220142935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 17/494555 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18994 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17472421 [patent_doc_number] => 20220079925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => COMPOSITIONS COMPRISING TACROLIMUS FOR THE TREATMENT OF INTRAOCULAR INFLAMMATORY EYE DISEASES [patent_app_type] => utility [patent_app_number] => 17/486634 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17486634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692496 [patent_doc_number] => 20230322771 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => HETEROCYCLIC GLP-1 AGONISTS [patent_app_type] => utility [patent_app_number] => 18/044196 [patent_app_country] => US [patent_app_date] => 2021-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -203 [patent_words_short_claim] => 1066 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18221183 [patent_doc_number] => 20230060177 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => METHOD FOR TREATING ATHLETES SUBJECT TO PATHOLOGICAL CARDIAC HYPERTROPHY BY ADMINISTERING NIGELLA SATIVA [patent_app_type] => utility [patent_app_number] => 17/406895 [patent_app_country] => US [patent_app_date] => 2021-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12603 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17406895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858498 [patent_doc_number] => 11439636 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-09-13 [patent_title] => Bupropion as a modulator of drug activity [patent_app_type] => utility [patent_app_number] => 17/405429 [patent_app_country] => US [patent_app_date] => 2021-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 25 [patent_no_of_words] => 64127 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519227 [patent_doc_number] => 20220105075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => CHEMICAL COMPOSITIONS AND METHODS FOR ENHANCING TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 17/402807 [patent_app_country] => US [patent_app_date] => 2021-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17413994 [patent_doc_number] => 20220048898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE [patent_app_type] => utility [patent_app_number] => 17/401642 [patent_app_country] => US [patent_app_date] => 2021-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42612 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17401642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355312 [patent_doc_number] => 20220016108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE [patent_app_type] => utility [patent_app_number] => 17/401371 [patent_app_country] => US [patent_app_date] => 2021-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25435 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17401371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17412667 [patent_doc_number] => 20220047571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV2 INFECTION [patent_app_type] => utility [patent_app_number] => 17/402419 [patent_app_country] => US [patent_app_date] => 2021-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17256618 [patent_doc_number] => 20210369603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => DOSAGE FORM FOR VAPORIZATION AND SMOKING [patent_app_type] => utility [patent_app_number] => 17/400359 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272822 [patent_doc_number] => 20210379020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => COMPOUNDS FOR THE TREATMENT OF MALARIA [patent_app_type] => utility [patent_app_number] => 17/399589 [patent_app_country] => US [patent_app_date] => 2021-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15869 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17399589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272822 [patent_doc_number] => 20210379020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => COMPOUNDS FOR THE TREATMENT OF MALARIA [patent_app_type] => utility [patent_app_number] => 17/399589 [patent_app_country] => US [patent_app_date] => 2021-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15869 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17399589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398137 [patent_doc_number] => 20220040227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME [patent_app_type] => utility [patent_app_number] => 17/398156 [patent_app_country] => US [patent_app_date] => 2021-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17398156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17821478 [patent_doc_number] => 11426401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Bupropion as a modulator of drug activity [patent_app_type] => utility [patent_app_number] => 17/395222 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 25 [patent_no_of_words] => 63949 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17395222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398064 [patent_doc_number] => 20220040154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA [patent_app_type] => utility [patent_app_number] => 17/395059 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17395059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18227953 [patent_doc_number] => 20230066947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => Method for the augmentation of substance abuse therapies using cannabinoid formulations [patent_app_type] => utility [patent_app_number] => 17/394398 [patent_app_country] => US [patent_app_date] => 2021-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18672901 [patent_doc_number] => 20230310348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => USE OF ALVERINE OR ITS DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DYSFUNCTION ASSOCIATED WITH MITOCHONDRIAL COMPLEX I DEFICIENCIES [patent_app_type] => utility [patent_app_number] => 18/005137 [patent_app_country] => US [patent_app_date] => 2021-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005137 [rel_patent_id] =>[rel_patent_doc_number] =>)